[go: up one dir, main page]

ATE264914T1 - Antivirale proteine, dafür kodierende dna, und deren verwendung - Google Patents

Antivirale proteine, dafür kodierende dna, und deren verwendung

Info

Publication number
ATE264914T1
ATE264914T1 AT96913854T AT96913854T ATE264914T1 AT E264914 T1 ATE264914 T1 AT E264914T1 AT 96913854 T AT96913854 T AT 96913854T AT 96913854 T AT96913854 T AT 96913854T AT E264914 T1 ATE264914 T1 AT E264914T1
Authority
AT
Austria
Prior art keywords
antiviral proteins
antiviral
dna coding
conjugates
peptides
Prior art date
Application number
AT96913854T
Other languages
English (en)
Inventor
Michael R Boyd
Kirk R Gustafson
Robert H Shoemaker
James B Mcmahon
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE264914T1 publication Critical patent/ATE264914T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT96913854T 1995-04-27 1996-04-26 Antivirale proteine, dafür kodierende dna, und deren verwendung ATE264914T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/429,965 US5843882A (en) 1995-04-27 1995-04-27 Antiviral proteins and peptides
PCT/US1996/005908 WO1996034107A2 (en) 1995-04-27 1996-04-26 Antiviral proteins, dna coding sequences therefor, and uses thereof

Publications (1)

Publication Number Publication Date
ATE264914T1 true ATE264914T1 (de) 2004-05-15

Family

ID=23705488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913854T ATE264914T1 (de) 1995-04-27 1996-04-26 Antivirale proteine, dafür kodierende dna, und deren verwendung

Country Status (8)

Country Link
US (9) US5843882A (de)
EP (1) EP0836647B1 (de)
JP (2) JP3803115B2 (de)
AT (1) ATE264914T1 (de)
AU (1) AU707781B2 (de)
CA (1) CA2219105A1 (de)
DE (1) DE69632256T2 (de)
WO (1) WO1996034107A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6193982B1 (en) * 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
AU746809B2 (en) * 1995-04-27 2002-05-02 United States of America, represented by the Secretary, Department of Health and Human Services, The National Institutes of Health, The Antiviral proteins, DNA coding sequences therefor, and uses thereof
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US5843882A (en) * 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6428790B1 (en) * 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
DE19713543B4 (de) * 1997-04-02 2007-01-11 Pharma-Zentrale Gmbh Bakterielle Plasmide
ES2249838T3 (es) * 1997-07-11 2006-04-01 The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services Inmunogenos quimericos similares a la exotoxina a de pseudomonas.
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
US20020107582A1 (en) * 2001-02-07 2002-08-08 Ron Pollak Local area network for distributing controls to peripheral controllers on mechanized irrigation equipment
EP1456382B1 (de) * 2001-03-22 2007-08-08 The United States of America, represented by the Secretary, Department of Health and Human Services Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
RU2004109222A (ru) * 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
EP1478392A4 (de) * 2002-02-25 2006-10-11 Us Gov Health & Human Serv Obligates domänentausch-dimer von cyanovirin mit verbesserter antiviraler wirksamkeit
US7179458B2 (en) * 2002-03-08 2007-02-20 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
EP1515738B1 (de) * 2002-05-16 2012-12-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Scytovirine und verwandte konjugate, fusionsproteine, nukleinsäuren, vektoren, wirtszellen, zusammensetzungen, antikörper und verfahren zur verwendung von scytovirinen
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
AU2003262886A1 (en) * 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US7379700B2 (en) * 2003-05-06 2008-05-27 Canon Kabushiki Kaisha Image reading apparatus with rotatable internal and external guides
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
WO2005021579A2 (en) * 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
AU2005222381B2 (en) * 2004-03-09 2010-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MVL, an antiviral protein from a cyanobacterium
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
ATE511848T1 (de) 2004-08-25 2011-06-15 Us Gov Health & Human Serv Lebendige mikrobielle mikrobizide
EP2309269B1 (de) 2004-09-08 2016-10-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Zusammensetzungen und verfahren zur detektion von hiv-1/hiv-2 infektion
KR101209761B1 (ko) 2004-12-30 2012-12-06 에스케이케미칼주식회사 항암 활성을 갖는 노스톡 엘립소스포룸 추출물
WO2006083516A2 (en) * 2005-01-12 2006-08-10 Osel, Inc. Modified cyanovirin-n polypeptide
EP2314320A2 (de) * 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Verfahren zur Abschirmung von funktionalen Stellen oder Epitopen von Proteinen
WO2007005766A1 (en) * 2005-07-05 2007-01-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Genomic nucleic acid sequence for cyanovirin-n and signal peptide thereof
US8088729B2 (en) 2005-12-01 2012-01-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Anti-viral griffithsin compounds, compositions and methods of use
US8093046B2 (en) * 2006-05-31 2012-01-10 Philadelphia Health and Education Corporation d/b/c Drexel University College of Medicine CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions
JP5102833B2 (ja) * 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション エキセンディン融合タンパク質
WO2008072075A2 (en) 2006-12-12 2008-06-19 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
CN101210164B (zh) * 2006-12-30 2011-04-20 上海轻工业研究所有限公司 聚酰胺热熔胶及用其粘接的鞋
US20080260725A1 (en) * 2007-03-29 2008-10-23 Ulhas Naik Tag and target delivery system
CA2700841A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US9212208B2 (en) * 2008-01-30 2015-12-15 Pieris Ag Muteins with tear lipocalin having affinity to human c-Met receptor tyrosine kinase and methods for obtaining the same
US10492817B2 (en) 2009-03-09 2019-12-03 A.M. Surgical, Inc. Endoscopic surgical blade and use thereof
CN101638435B (zh) * 2009-09-04 2011-11-16 暨南大学 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用
US8911728B2 (en) 2010-05-21 2014-12-16 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins
WO2012142459A1 (en) 2011-04-14 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US20160039904A1 (en) 2013-03-15 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Stabilized single human cd4 domains and fusion proteins
AU2015204680B2 (en) 2014-01-09 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-viral cnidarins
LT3256486T (lt) 2015-02-10 2020-06-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Grifitzino mutantai
EP3590961A1 (de) 2015-03-25 2020-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispezifische multivalente fusionsproteine
WO2018039626A1 (en) 2016-08-25 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human single domain antibodies targeting cd16a to mediate adcc
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019108656A1 (en) 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microbicidal composition
CN110331152B (zh) * 2019-07-11 2021-06-18 太极集团有限公司 粉棒束孢Cyanovirin-N基因、重组蛋白及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266478A (en) 1987-05-29 1993-11-30 Tanox Biosystems, Inc. Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
US5445960A (en) 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
DE69029937T2 (de) 1989-04-25 1997-05-28 Tanox Biosystems Inc FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER
WO1991009625A1 (en) 1989-12-21 1991-07-11 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes
SE9000333D0 (sv) 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
ATE175446T1 (de) 1990-05-16 1999-01-15 Dana Farber Cancer Inst Inc Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
JP2989862B2 (ja) 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体
CA2094713A1 (en) 1990-10-26 1992-04-27 Shermaine A. Tilley Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
AU8900691A (en) 1990-11-19 1992-06-11 Queen's University At Kingston Hiv marker/aids vaccine
WO1992008491A1 (en) 1990-11-20 1992-05-29 Tanox Biosystems, Inc. Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
IE920785A1 (en) 1991-03-11 1992-09-23 Idec Pharma Corp Methods for selecting antibody reagents; anti-idiotype¹antibodies; and aids vaccine formulations
WO1992015885A1 (en) 1991-03-11 1992-09-17 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
JPH0570493A (ja) 1991-05-31 1993-03-23 Chemo Sero Therapeut Res Inst ヒト免疫不全ウイルス（ｈｉｖ）関連免疫調製物
WO1994004574A1 (en) 1991-08-22 1994-03-03 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
EP0554446B1 (de) 1991-08-22 1998-11-04 Nissin Shokuhin Kabushiki Kaisha In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper
AU2752892A (en) * 1991-09-26 1993-04-27 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
CA2125396A1 (en) 1991-12-10 1993-06-24 Wayne A. Marasco Reactive neutralizing human anti-gp 120 recombinant antibody, dna coding the same and use thereof
EP0581353A1 (de) 1992-07-03 1994-02-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Monoklonale Antikörper gegen HIV-1 gp120, Zellinien die sie herstellen und entsprechende Epitope-Strukturen
ES2194015T3 (es) 1992-09-30 2003-11-16 Scripps Research Inst Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
US5817767A (en) 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
AU7203194A (en) 1993-06-04 1995-01-03 New York University Bispecific human monoclonal antibodies specific for human immunodeficiency virus
CA2170034C (en) 1993-08-24 2005-03-15 Joseph William Harris Recombinant humanized anti-human immunodeficiency virus antibody
IT1272682B (it) * 1993-09-24 1997-06-26 Pietro Antonino Di Struttura di profilattico a doppia membrana
US5618922A (en) 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
US5843882A (en) * 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US5962668A (en) * 1995-04-27 1999-10-05 The United States Of America As Represented By The Department Of Health And Human Services Nucleic acids encoding antiviral proteins and peptides fused to effector proteins

Also Published As

Publication number Publication date
JP4081484B2 (ja) 2008-04-23
JP2006094860A (ja) 2006-04-13
US6245737B1 (en) 2001-06-12
US20020151476A1 (en) 2002-10-17
AU707781B2 (en) 1999-07-22
EP0836647A2 (de) 1998-04-22
US6015876A (en) 2000-01-18
US5998587A (en) 1999-12-07
WO1996034107A2 (en) 1996-10-31
US6420336B1 (en) 2002-07-16
JP3803115B2 (ja) 2006-08-02
AU5669196A (en) 1996-11-18
US5962653A (en) 1999-10-05
DE69632256D1 (de) 2004-05-27
CA2219105A1 (en) 1996-10-31
DE69632256T2 (de) 2005-04-14
US20030103997A1 (en) 2003-06-05
US6743577B2 (en) 2004-06-01
US5843882A (en) 1998-12-01
JPH11504804A (ja) 1999-05-11
EP0836647B1 (de) 2004-04-21
WO1996034107A3 (en) 1997-04-24
US5821081A (en) 1998-10-13
US6586392B2 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
TR199903053T2 (xx) Benzimidazol t�revleri.
DE69738535D1 (de) Antivirale mittel aus pflanzenextrakten und deren verwendung zur behandlung viraler infektionen
DK0689447T3 (da) Cytopatiske vira til behandling af og profylakse for neoplasia
MXPA02006679A (es) Composicion farmaceutica.
HUP0400882A2 (hu) Onkolitikus vírusterápia
DK0958371T3 (da) Cytopatiske vira til behandling og forebyggelse af neoplasi
ATE84217T1 (de) Fragmente und fraktionen von heparin mit wirkung gegen hiv.
TR200102024T2 (tr) Yeni tedavi.
EP0681578A1 (de) Gegen virussen wirksam naphtochinon verbindungen, zusammensetzungen und deren verwendungen.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
ATE374208T1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
DK0777669T3 (da) 4-[2-amino-6-(cyclopropylamino)-9H-purin-yl]-2-cyclopenten-1-methanolsuccinat som antiviralt middel
DK0633887T3 (da) Antivirale calanolidforbindelser, præparater og anvendelser deraf
BR0314657A (pt) Inibidores de fusão de derivados de peptìdeo de infecção de hiv
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
DE60143668D1 (de) Peptidinhibitoren gegen den eintritt von hiv in zellen
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
DK0545991T3 (da) Peptider, der blokerer infektioner med human immundefektvirus, og fremgangsmåder til anvendelse deraf
FI943295A0 (fi) Piliostigma thonningii -uutteet, niiden käyttö ja Piliostigma thonningii -uutteet, niiden käyttö ja niitä sisältävät formuloinnit niitä sisältävät formuloinnit
BR0207931A (pt) Anticorpos naturais ativos contra vìrus hiv
James T-20 and Trimeris
FR2610632B1 (fr) Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties